NVP-BHG712

inquiry

Cat No.

CEI-0158

Description

NVP-BHG712 can inhibit c-Raf, c-Src and c-Abl with IC50 of 0.395 uM, 1.266 uM and 1.667 uM.

CAS_No

940310-85-0

Molecular Weight

503.48

Purity

>99%

Storage

2 years at -20centigrade Powder

Targets

c-Raf, c-Src, c-Abl

Molecular Formula

C26H20F3N7O

Chemical Name

4-methyl-3-(1-methyl-6-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamino)-N-(3-(trifluoromethyl)phenyl)benzamide

Solubility

DMSO 101 mg/mL Water

In vitro

As a small molecular weight kinase inhibitor of the EphB4 kinase, NVP-BHG712, which inhibits EphB4 kinase activity in the low nanomolar range in cellular assays. NVP-BHG712 shows excellent pharmacokinetic properties and potently inhibits EphB4 autophosphorylation in tissues after oral administration. In vivo, NVP-BHG712 inhibits VEGF driven vessel formation, while it has only little effects on VEGF receptor (VEGFR) activity in vitro or in cellular assays. NVP-BHG712 can inhibit VEGF induced angiogenesis through inhibiting EphB4, because EphB4 plays an important role in VEGF induced angiogenesis.

In vivo

After oral administration, NVP-BHG712 shows excellent pharmacokinetic properties and potently inhibits EphB4 autophosphorylation in tissues. In vivo, NVP-BHG712 inhibits VEGF driven vessel formation, while it has only little effects on VEGF receptor (VEGFR) activity .

Name:

Email *

Phone:*

Company/Institution:

Country or Region:

Quantity:

Services & Products Interested *

Project Description:

Our Products Cannot Be Used As Medicines Directly For Personal Use.

Products

Online Inquiry